ABSTRACT
Introduction
In 2013, an estimated 110,110 women in the U.S. were diagnosed with lung cancer and 72,220 died from this disease 1 . There remains a gender gap in incidence rates with men having higher rates than women, but with the declining incidence among men and the leveling off of incidence among women only recently, this gender difference is narrowing. The lifetime risk of developing lung cancer is 6.9% in both men and women 1 .
While approximately 90% of lung cancer deaths are attributable to cigarette smoking in men, only 75-80% of lung cancer deaths in women are attributable to smoking 2 . There has been considerable debate about differences in lung cancer occurrence and characteristics between men and women. Women are more likely to have adenocarcinomas of the lung (45.0%) than men (37.2%) and are more likely to have tumors with EGFR mutations 3 . Women who never smoked are also more likely to develop lung cancer than men who have never smoked [4] [5] [6] [7] . However, the 5-year relative survival after a lung cancer diagnosis is better for women than for men (20.0% and 15.4%, respectively) 1 . Taken together, male-female differences in lung cancer risk, tumor characteristics and outcome have fueled investigations into the role of estrogens in lung cancer risk and prognosis.
Epidemiologic studies of estrogen as a risk factor for lung cancer have focused on reproductive and estrogen use history. Findings have been inconsistent, with reports of increased and decreased risk associated with post-menopausal hormone therapy (HT), oral contraceptive (OC) use, pregnancy and menstrual history . The Women's Health Initiative (WHI) clinical trials data demonstrated that neither the use of estrogen A C C E P T E D plus progestin or estrogen alone was associated with lung cancer incidence 18, 19 . Taken as a whole, inconsistent findings across studies are likely due to a number of factors including variations in HT dosing over time and potential misclassification of exposures, however, they suggest a possible role for exogenous estrogens (i.e., HT, OCs) in the development of lung cancer.
We evaluated the role of reproductive factors and hormone use in determining risk of lung cancer in women from both the Women's Health Initiative Observational Study (WHIOS) and Clinical Trials (CTs).
Methods

The Women's Health Initiative
The WHI enrolled a geographically and ethnically diverse cohort of 161,808 postmenopausal women age 50-79 years between October 1, 1993 and December 31, 1998 at 40 centers across the United States. All participants provided informed consent.
Women were enrolled in one of four randomized CTs testing use of estrogen alone or estrogen plus progestin, calcium plus vitamin D (CaD), or low fat diet (dietary modification-DM) on several outcomes. In addition, the OS enrolled women who provided detailed lifestyle and medical history and were followed for disease outcomes.
Details of recruitment 32 and baseline characteristics of study participants 33 have been published previously. Reproductive history (age at first birth, number of pregnancies, age at menarche, age at menopause, bilateral oophorectomy), use of unopposed estrogens, estrogen plus progesterone and/or oral contraceptives (never used, duration of use <5, 5-9, 10-14, 15+ years), were collected at the baseline clinic visit by self-
report. Current users of hormone therapy (HT) were defined as women using HT at baseline in the OS, or women using HT at baseline in the DM or CaD trials (who were not participating in the HT trial) or women assigned to HT use in the HT CT. Past users of HT were defined as women not using HT at baseline in the OS, DM, or CaD CTs but who had used HT in the past, women receiving placebo in the HT CT but who had used HT in the past, or women randomized to HT who used HT in the past and completed a wash out period before going on trial. Never users of HT were defined as women never using HT in the OS or non-HT CTs or women on the placebo arm of the HT CT who had never used HT before trial initiation. Therefore, any of the participants, even those enrolled in the HT CT and randomized to HT, could have been defined as past users of HT.
The type of HT was classified as that reported at baseline for all women except for those on the intervention arm of the HT CT, for whom the assigned HT was used.
Duration of use was calculated from start of use to before baseline or randomization.
Self-report of age at enrollment, education, income, smoking status (never smoked more than 100 cigarettes, ever smoked more than 100 cigarettes), number of cigarettes review of medical records and pathology reports. As of September 17, 2012, 2,467 lung cancers had been reported and centrally adjudicated. Of these, 2,220 were classified as non-small cell lung cancers (NSCLC), 236 were classified as small cell lung cancers (SCLC) and 11 had missing histology.
Statistical Approach
The baseline subject questionnaire data, supplemented with data on lung cancer incidence, were used in the analysis. The primary objective of this study was to assess the association of reproductive history and use of oral contraceptives and hormone therapy, after adjustment for tobacco use and other known lung cancer risk factors, with risk of lung cancer among women. Two hundred fifty-seven women who reported a history of lung cancer on the baseline questionnaire were excluded. In addition, 696
women who were enrolled in the WHI studies but for whom there was no follow-up information were also excluded, leaving 160,855 women in this analysis, with 2,467 incident cases of lung cancer.
Associations between reproductive and hormonal factors and lung cancer incidence were assessed using Cox regression models to compute adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). Time to incident lung cancer was computed as days from randomization in the CTs or enrollment in the OS to the first diagnosis of lung cancer during follow-up. Otherwise, follow-up was censored at the last documented follow-up contact, death, or September 17, 2012, whichever came first. Additional analyses were conducted, stratified by baseline smoking status (never, former, current) and in relation to risk by lung cancer histology (SCLC, NSCLC, and specific NSCLC subtypes Statistical tests were two-sided, and p values less than 0.05 were considered statistically significant. All analyses were performed using the SAS system, version 9.3 (SAS Institute, Cary, NC, USA). Table 1 presents the baseline characteristics of the 160,855 women included in the analysis stratified by lung cancer status. In the entire cohort, 2,467 lung cancers were diagnosed during follow-up. After adjustment for multiple factors (see Methods and footnote on Table 2 ), the only variables in which there was a statistically significant relationship with lung cancer risk overall, and NSCLC specifically, included later age at first live birth and later age at menopause, both of which were associated with a reduced risk. Increasing time since menopause was associated with an increased risk ( Table 2 ).
RESULTS
The only statistically significant findings with regard to hormone use were a reduction in risk associated with previous use of estrogen plus progestin of less than 5 years for all lung cancers (HR=0.84; 95% CI 0.72-0.98) and a similar reduction in risk associated with 5 to <10 years of any previous hormone use for NSCLC (HR=0.84; 95% CI 0.71-0.99). Little variation in risk in association with hormone use was seen for subtypes of NSCLC including adenocarcinomas, squamous cell carcinomas, large cell and associated subtypes, and other NSCLC or unspecified NSCLC (data not shown).
There were no significant relationships to risk of SCLC. smokers only, women with 5 or more live births were at 34% increased risk and women with 10 or more years of previous use of estrogen plus progestin were at 62% increased risk, but this trend in risk associated with duration of use was not statistically significant.
A C C E P T E D
Discussion
This study found no consistent contributions to lung cancer risk for a wide range of reproductive history measures. This is an area in which the epidemiologic literature has been inconsistent. Decades ago, studies of adenocarcinoma of the lung reported that early age at menopause was associated with decreased risk 8
, and non-significant increases in risk were associated with later age at menarche, surgical menopause or early menopause and hormone use 22 . Other studies have reported no association between lung cancer risk and reproductive factors 12, 27 , increased risk associated with increased parity 28 , or decreased risk with increasing age at first live birth 10 . In cohort studies, adenocarcinoma risk was reduced with late menarche and increased with early age at menopause (including that resulting from bilateral oophorectomy particularly prior to age 40)
16
, and overall lung cancer risk was increased in women having 5 or more children, a finding we replicated only among current smokers, while decreased for women giving birth for the first time after age 30 31 . Boggs et al. report non-significant increased risk of lung cancer in African American women with a history of bilateral oophorectomy before age 40 and fewer than 2 years of hormone use 34 . We found that bilateral oophorectomy was differentially associated with lung cancer risk; risk was increased in never smokers (HR=1.47; 95% HR 1.00-2.16; p=0.049) and decreased in smokers (HR=0.68; 95% CI 0.51-0.90). These findings need further exploration to untangle contributions from the underlying reason for bilateral oophorectomy, age at surgery, hormone use before and after surgery, and timing of cigarette exposure.
A C C E P T E D
Overall, however, published work, like our study, does not support the idea that reproductive history independently contributes to lung cancer risk. While not a primary analysis topic for this study, an important note is that 55% of the lung cancers were diagnosed among former smokers. We estimated, based on the data available, that 69% of these former smokers had quit smoking more than 15 years before lung cancer diagnosis. This suggests that there is a large population of longer term women former smokers at risk.
This study has several strengths including its prospective nature and large sample size. The prospective design allowed for collection of exposure data before lung cancer diagnosis. However, there were also some limitations. While the CT data provide the best opportunity for understanding the relationship between HT use and lung cancer risk, only a small number of lung cancer cases developed in the CT arms.
All study arms collected smoking dose and duration as categorical variables, and In conclusion, this large, prospective study of lung cancer in women did not find strong associations with specific reproductive variables and risk, and provided only weak support for a role of hormone use in the etiology of lung cancer. There remain questions about estrogen and lung cancer risk that will not easily be answered by studies focusing on hormone use. The interplay between cigarette smoking, estrogen, genetic susceptibility and lung cancer is complex and continued study is necessary to tease apart these relationships.
